These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 29487226)

  • 1. Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.
    Alvarez RH; Bechara RI; Naughton MJ; Adachi JA; Reuben JM
    Oncologist; 2018 Jun; 23(6):660-669. PubMed ID: 29487226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
    Peddi PF; Shatsky RA; Hurvitz SA
    Cancer Treat Rev; 2014 Mar; 40(2):320-6. PubMed ID: 24011786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E; Zelnak A; O'Regan R
    Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.
    Yardley DA
    Clin Breast Cancer; 2014 Oct; 14(5):297-308. PubMed ID: 25065566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
    Duran I; Goebell PJ; Papazisis K; Ravaud A; Weichhart T; Rodriguez-Portal JA; Budde K
    Expert Opin Drug Saf; 2014 Mar; 13(3):361-72. PubMed ID: 24517115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer.
    Aapro M; Andre F; Blackwell K; Calvo E; Jahanzeb M; Papazisis K; Porta C; Pritchard K; Ravaud A
    Ann Oncol; 2014 Apr; 25(4):763-773. PubMed ID: 24667713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
    White DA; Camus P; Endo M; Escudier B; Calvo E; Akaza H; Uemura H; Kpamegan E; Kay A; Robson M; Ravaud A; Motzer RJ
    Am J Respir Crit Care Med; 2010 Aug; 182(3):396-403. PubMed ID: 20194812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer.
    Rugo HS
    Clin Breast Cancer; 2016 Feb; 16(1):18-22. PubMed ID: 26507507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in Waldenström Macroglobulinemia as a Paradigm.
    Nishino M; Boswell EN; Hatabu H; Ghobrial IM; Ramaiya NH
    Oncologist; 2015 Sep; 20(9):1077-83. PubMed ID: 26205737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
    Ng VC; Johnson JJ; Cuellar S
    J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
    Peterson ME
    Support Care Cancer; 2013 Aug; 21(8):2341-9. PubMed ID: 23686401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
    Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.
    Rugo HS; Pritchard KI; Gnant M; Noguchi S; Piccart M; Hortobagyi G; Baselga J; Perez A; Geberth M; Csoszi T; Chouinard E; Srimuninnimit V; Puttawibul P; Eakle J; Feng W; Bauly H; El-Hashimy M; Taran T; Burris HA
    Ann Oncol; 2014 Apr; 25(4):808-815. PubMed ID: 24615500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB; Bivona C; Medina PJ
    Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
    Dabydeen DA; Jagannathan JP; Ramaiya N; Krajewski K; Schutz FA; Cho DC; Pedrosa I; Choueiri TK
    Eur J Cancer; 2012 Jul; 48(10):1519-24. PubMed ID: 22483544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
    Chambers MS; Rugo HS; Litton JK; Meiller TF
    J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
    White DA; Schwartz LH; Dimitrijevic S; Scala LD; Hayes W; Gross SH
    J Thorac Oncol; 2009 Nov; 4(11):1357-63. PubMed ID: 19745764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.
    Divers J; O'Shaughnessy J
    Clin J Oncol Nurs; 2015 Aug; 19(4):468-74. PubMed ID: 26207713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
    Willemsen AE; Grutters JC; Gerritsen WR; van Erp NP; van Herpen CM; Tol J
    Int J Cancer; 2016 May; 138(10):2312-21. PubMed ID: 26452336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach.
    Nishino M; Brais LK; Brooks NV; Hatabu H; Kulke MH; Ramaiya NH
    Eur J Cancer; 2016 Jan; 53():163-70. PubMed ID: 26760924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.